Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>If you are still long the <a href="https://www.smartkarma.com/entities/hokuhoku-financial-group-inc" target="_blank" data-smartkarma-citation="entities:19006:1" rel="noopener">Financial Group (8377 JP)</a> from before, stay long.If you sold Hokuhoku from before, be long again, and buy on weakness</li>
<li>Disaster for arb players as AusSuper rewrites the record books as an investor class and shoots down Brookfield's sweetened Offer for <a href="https://www.smartkarma.com/entities/origin-energy-ltd" target="_blank" data-smartkarma-citation="entities:797:1" rel="noopener">Origin Energy (ORG AU)</a>.</li>
<li>
<a href="https://www.smartkarma.com/entities/kyocera-corp" target="_blank" data-smartkarma-citation="entities:753:1" rel="noopener">Kyocera (6971 JP)</a> announced Q2 results and lowered its full-year forecast. Then the CEO said it was "reconsidering" what to do with <a href="https://www.smartkarma.com/entities/kddi-corp" target="_blank" data-smartkarma-citation="entities:639:1" rel="noopener">KDDI (9433 JP)</a> shares (after an AGM disaster).</li>
</ul>


If you are still long the Financial Group (8377 JP) from before, stay long.If you sold Hokuhoku from before, be long again, and buy on weakness
Disaster for arb players as AusSuper rewrites the record books as an investor class and shoots down Brookfield's sweetened Offer for Origin Energy (ORG AU).

Kyocera (6971 JP) announced Q2 results and lowered its full-year forecast. Then the CEO said it was "reconsidering" what to do with KDDI (9433 JP) shares (after an AGM disaster).


Last Week in Event SPACE: Hokuhoku, Origin Energy, KDDI, BoJ

European Event-Driven Analyst

Jesus Rodriguez Aguilar

<ul>
<li>The $26.00/share cash offer of <a href="https://www.smartkarma.com/entities/thermo-fisher-scientific-inc-49322cfa-b354-4c3d-ac3b-f4e91aead32b" target="_blank" data-smartkarma-citation="entities:26834:1" rel="noopener">Thermo Fisher Scientific (TMO UN)</a> for Swedish <a href="https://www.smartkarma.com/entities/olink-holding-ab" target="_blank" data-smartkarma-citation="entities:36991:1" rel="noopener">Olink Holding (OLK US)</a> started on 31 October. The 74% premium reflects that high-growth, positive adjusted EBITDA targets are rare.</li>
<li>The offer values Olink at ~12.2x EV/NTM Fwd revenue vs. 6.4x median of peers. Irrevocables total 66%, but the minimum acceptance condition requires acceptances from a high 70.6% of float. </li>
<li>Barring any unforeseen circumstances, such as regulatory action, I anticipate the deal closing and set my TP at $26/share. Gross spread is 4.81%.</li>
</ul>


The $26.00/share cash offer of Thermo Fisher Scientific (TMO UN) for Swedish Olink Holding (OLK US) started on 31 October. The 74% premium reflects that high-growth, positive adjusted EBITDA targets are rare.
The offer values Olink at ~12.2x EV/NTM Fwd revenue vs. 6.4x median of peers. Irrevocables total 66%, but the minimum acceptance condition requires acceptances from a high 70.6% of float. 
Barring any unforeseen circumstances, such as regulatory action, I anticipate the deal closing and set my TP at $26/share. Gross spread is 4.81%.


Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Thermo Fisher Scientific Inc / Equity Bottom-Up

<ul><li>Thermo Fisher Scientific delivered a disappointing set of results as the company was unable to meet the revenue and earnings expectations of Wall Street.</li><li>The company has been enhancing its commercial intensity in the quarter to assist its customers through the environment and seize more opportunities.</li><li>During the quarter, Thermo Fisher delivered good core business growth driven by its transplant diagnostic, immunodiagnostics, and microbiology businesses.</li></ul>

Thermo Fisher Scientific delivered a disappointing set of results as the company was unable to meet the revenue and earnings expectations of Wall Street.The company has been enhancing its commercial intensity in the quarter to assist its customers through the environment and seize more opportunities.During the quarter, Thermo Fisher delivered good core business growth driven by its transplant diagnostic, immunodiagnostics, and microbiology businesses.

Thermo Fisher Scientific Inc.: Can The Acquisition of CorEvitas Be A Game Changer? – Key Drivers

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>The three companies we write about this week are <a href="https://www.smartkarma.com/entities/raytheon-technologies-corp" target="_blank" data-smartkarma-citation="entities:6453:1" rel="noopener">Raytheon Technologies (RTX US)</a><a href="https://www.smartkarma.com/entities/beiersdorf-ag" target="_blank" data-smartkarma-citation="entities:21588:1" rel="noopener">Beiersdorf AG (BEI GR)</a> and <a href="https://www.smartkarma.com/entities/king-slide-works-co-ltd" target="_blank" data-smartkarma-citation="entities:7130:1" rel="noopener">King Slide Works (2059 TT)</a> 
</li>
<li>For the twenty-six weeks since inception ended 19 May the combined innovation portfolio was +2.5%, versus DJIA-0.9%, S&amp;P500+5.7%, Nasdaq+13.6%, Russell2000 -4.1%, MSCI-ACWI-ETF+6.9%, S&amp;P midcap 400 -2.2%, all in US$ terms</li>
<li>Small-Cap (+4.1%) versus Russell2000 (-4.1%) and midcap (+1.9%) versus S&amp;P400 (-2.2%) continues to outperform benchmarks, but the omission of mega-tech names has hurt large-cap portfolio (+2.6%) versus S&amp;P500 (+5.7%) . </li>
</ul>


The three companies we write about this week are Raytheon Technologies (RTX US)Beiersdorf AG (BEI GR) and King Slide Works (2059 TT) 

For the twenty-six weeks since inception ended 19 May the combined innovation portfolio was +2.5%, versus DJIA-0.9%, S&amp;P500+5.7%, Nasdaq+13.6%, Russell2000 -4.1%, MSCI-ACWI-ETF+6.9%, S&amp;P midcap 400 -2.2%, all in US$ terms
Small-Cap (+4.1%) versus Russell2000 (-4.1%) and midcap (+1.9%) versus S&amp;P400 (-2.2%) continues to outperform benchmarks, but the omission of mega-tech names has hurt large-cap portfolio (+2.6%) versus S&amp;P500 (+5.7%) . 


The Innovations Portfolios - Week Twenty Six

<ul><li>Thermo Fisher performed reasonably well in Q1 with 6% core organic revenue growth that was above Wall Street expectatis.</li><li>Pandemic-related revenue came in as expected, with $140 million of testing revenue and $180 million of vaccines and therapies revenue.</li><li>Regarding the segment details, the Life Sciences Solutions segment reported a decline in revenue and organic revenue, driven by the moderation in pandemic-related revenue.</li></ul>

Thermo Fisher performed reasonably well in Q1 with 6% core organic revenue growth that was above Wall Street expectatis.Pandemic-related revenue came in as expected, with $140 million of testing revenue and $180 million of vaccines and therapies revenue.Regarding the segment details, the Life Sciences Solutions segment reported a decline in revenue and organic revenue, driven by the moderation in pandemic-related revenue.

Thermo Fisher Scientific Inc.: The GeneProof Partnership & Other Developments

United States

Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals. The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Thermo Fisher Scientific (TMO UN)

Last Week in Event SPACE: Hokuhoku, Origin Energy, KDDI, BoJ

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

David Blennerhassett

Start of Tender Offer

Thermo Fisher Scientific offers $26/share for Olink Holding, 12.2x EV/NTM Fwd revenue, higher than peers, 74% premium due to rare high-growth,...

Jesus Rodriguez Aguilar

Thermo Fisher Scientific Inc.: Can The Acquisition of CorEvitas Be A Game Changer? – Key Drivers

Thermo Fisher Scientific delivered a disappointing set of results as the company was unable to meet the revenue and earnings expectations of Wall...

Baptista Research

The Innovations Portfolios - Week Twenty Six

The small-Cap (+4.1%) and midcap (+1.9%) portfolios continues to outperform respective benchmarks, but the willful omission of mega-tech names has...

Pyari Menon

Thermo Fisher Scientific Inc.: The GeneProof Partnership & Other Developments

Thermo Fisher performed reasonably well in Q1 with 6% core organic revenue growth that was above Wall Street expectatis. Pandemic-related revenue...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Last Week in Event SPACE: Hokuhoku, Origin Energy, KDDI, BoJ

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

David Blennerhassett

Start of Tender Offer

​Thermo Fisher Scientific offers $26/share for Olink Holding, 12.2x EV/NTM Fwd revenue, higher than peers, 74% premium due to rare high-growth,...

Jesus Rodriguez Aguilar

Thermo Fisher Scientific Inc.: Can The Acquisition of CorEvitas Be A Game Changer? – Key Drivers

Thermo Fisher Scientific delivered a disappointing set of results as the company was unable to meet the revenue and earnings expectations of Wall...

Baptista Research

The Innovations Portfolios - Week Twenty Six

The small-Cap (+4.1%) and midcap (+1.9%) portfolios continues to outperform respective benchmarks, but the willful omission of mega-tech names has...

Pyari Menon

Thermo Fisher Scientific Inc.: The GeneProof Partnership & Other Developments

Thermo Fisher performed reasonably well in Q1 with 6% core organic revenue growth that was above Wall Street expectatis. Pandemic-related revenue...

Baptista Research

Thermo Fisher Scientific offers $26/share for Olink Holding, 12.2x EV/NTM Fwd revenue, higher than peers, 74% premium due to rare high-growth,...